Agency Succession Planning: Internal Sale, External Sale, Perpetuation, and the ESOP Question

The numbers describe the problem better than any thesis could. The 2022 Agency Universe Study put the average agency principal at 54 years old, with 17% of principals 66 or older and 4 in 10 agencies anticipating an ownership change within five years. More than 8 in 10 agencies report having a perpetuation plan. But the 2020 edition of the same study found as many as 83% of agencies have no written succession plan. The distance between a plan that exists in the principal’s head and one that is written, valued, and funded is the working definition of succession risk, and it is where this guide starts.

The four paths

Internal sale to producers. The agency sells over time to one or more validated producers, usually on a seller-financed note supplemented by bank or SBA-guaranteed lending. The prerequisite is not willingness but validation: a buyer whose book demonstrably covers their own compensation can service acquisition debt, and one who cannot, cannot. The price mechanics differ from an external sale at the root: an internal price comes from a formula in the buy-sell agreement or a standing valuation, not from an auction, so the market premium a competitive process produces is precisely what the seller is choosing to forgo in exchange for continuity and control of terms. The market reference points live in the valuation guide.

External sale. The competitive-process path: strategic buyers and PE-backed aggregators, marketed by an advisor, priced off EBITDA with structures that typically mix cash, earn-outs, and rollover equity. The current market data, deal volumes, and multiple ranges are maintained in the M&A market analysis, and the process mechanics in the advisor guide. What matters for succession purposes: this is the path with the highest headline price, the shortest principal timeline after close, and the least post-close control over staff, brand, and culture.

Gradual perpetuation. Family transfer or a widening internal ownership group, executed across years by design: annual gifting or sale tranches, governance that adds owners before it subtracts the founder, and key-person coverage on the people the plan depends on. This is the path the Agency Universe data says most agencies intend, and the one most exposed to the written-plan gap, because a multi-year transfer that lives in intentions rather than documents does not survive a death, a divorce, or a falling-out.

ESOP. The agency sells to a trust owned by employees. The federal tax mechanics are the draw: under 26 U.S.C. § 1042, a seller of qualified securities to an ESOP can defer capital gain by reinvesting in qualified replacement property within a window running from 3 months before to 12 months after the sale, provided the ESOP holds at least 30% of the company immediately afterward. Replacement property means securities of a domestic operating corporation that is not the same company and whose passive income does not exceed 25% of gross receipts. In practice the deferral has lived in C corporations; a 2022 amendment loosens that restriction for sales occurring after December 31, 2027. The costs are structural and permanent: an independent trustee, annual valuations, ERISA compliance, and a repurchase obligation to departing employee-owners that the agency must fund forever.

Connelly changed the buy-sell math

Most internal and perpetuation paths are backed by a buy-sell agreement funded with life insurance, and in June 2024 the Supreme Court changed how that structure values at death. In Connelly v. United States (decided unanimously, June 6, 2024), the company held life insurance on two brother-shareholders to fund redemption of a deceased brother’s shares. The Court held that the insurance proceeds are a corporate asset that increases the company’s date-of-death value, and that the obligation to redeem the shares does not offset them. In the case itself, $3 million of proceeds used for redemption pushed the decedent’s share value from the $3 million the estate filed to $5.3 million as the IRS calculated it, producing $889,914 of additional estate tax.

The practical consequence for agency principals: an entity-redemption buy-sell funded with corporate-owned life insurance now carries a valuation surprise for taxable estates that the documents may never have priced. The opinion itself points at the alternative, a cross-purchase structure where each owner holds a policy on the other personally, while acknowledging it has drawbacks of its own, mostly policy count and premium mechanics as owner groups grow. Estate counsel spent the following year publishing alerts with titles like “It’s Time to Revisit Buy-Sell Agreements,” which is an accurate summary of the homework: any agency whose perpetuation depends on a redemption-style agreement drafted before mid-2024 is running on pre-Connelly math.

Tax shape, structurally

The recurring tax fork in every path is asset sale versus stock sale: buyers of assets get a stepped-up basis to amortize and leave historical liabilities behind, sellers of stock get capital-gain treatment on the whole position, and the negotiation over that difference is priced into every deal. Installment treatment spreads gain across the years payments actually arrive, which is the default texture of seller-financed internal deals. The § 1042 deferral above is the ESOP-specific lever. Everything past those mechanics, including state tax treatment and entity-specific planning, varies enough by situation that it belongs to the agency’s CPA and counsel, engaged before a path is chosen rather than after.

What a written plan actually contains

The 83% statistic is not about intentions; it is about documents. The written version of any path answers, on paper: who buys, at what price or formula, funded how, triggered by what events (death, disability, departure, deadlock), governed by whom during the transition, and reviewed on what schedule. A buy-sell or succession agreement that names the mechanism but not the funding, or fixes a price formula nobody has tested against a current valuation, documents a plan that will not execute as written. The sequencing the paths share: a current valuation first, candidate and family conversations second, counsel and CPA before any structure is signed, and the funding instruments last, sized to the numbers the valuation produced. The one-way mistakes the trade coverage keeps documenting are starting the process at the intended retirement date instead of years ahead of it, and assuming a producer can finance a purchase no lender has looked at.

This guide is on an annual review cycle; the Connelly section gets updated as post-2024 guidance and case law develop.